Effectiveness of sotalol treatment in symptomatic Brugada syndrome
KA Glatter, Q Wang, M Keating, S Chen… - The American journal of …, 2004 - Elsevier
KA Glatter, Q Wang, M Keating, S Chen, N Chiamvimonvat, MM Scheinman
The American journal of cardiology, 2004•ElsevierWe describe a 53-year-old man with recurrent syncopal events and a malignant family
history who was treated for 13 years with sotalol drug therapy with no further occurrence of
Brugada syndrome symptoms. Genetic testing revealed that he carried a Brugada syndrome
sodium channel SCN5A mutation (4189delT). This finding suggests that sotalol may be of
therapeutic benefit in such patients.
history who was treated for 13 years with sotalol drug therapy with no further occurrence of
Brugada syndrome symptoms. Genetic testing revealed that he carried a Brugada syndrome
sodium channel SCN5A mutation (4189delT). This finding suggests that sotalol may be of
therapeutic benefit in such patients.
We describe a 53-year-old man with recurrent syncopal events and a malignant family history who was treated for 13 years with sotalol drug therapy with no further occurrence of Brugada syndrome symptoms. Genetic testing revealed that he carried a Brugada syndrome sodium channel SCN5A mutation (4189delT). This finding suggests that sotalol may be of therapeutic benefit in such patients.
Elsevier